Showing papers in "Drug Resistance Updates in 2015"

TL;DR: Methods to overcome the blood-brain tumor barrier barrier (BBTB) are provided, including osmotic blood- brain barrier disruption (BBBD), bradykinin receptor-mediated BBTB opening, inhibition of multidrug efflux transporters, receptor- mediated transport systems and physiological circumvention of the BBTB.

TL;DR: The development of new compounds and the re-evaluation of compounds originally designed for other targets as transport inhibitors of ATP-dependent drug efflux pumps are summarized.

TL;DR: The population structure, epidemiology, antimicrobial resistance mechanisms and virulence of the P. aeruginosa high-risk clones are reviewed and the aspects related to their detection in the clinical microbiology laboratory and the implications for infection control and public health are discussed.

TL;DR: L-AmB was recommended as core therapy for central nervous system aspergillosis suspected to be due to an azole-resistant Aspergillus, and the addition of a second agent with the majority favouring flucytosine was considered.

TL;DR: The current knowledge on intrinsic and environment-mediated gem citabine resistance is summarized, and the impact of these pathways on patient screening, and on future treatments aimed to potentiate gemcitabine activity is discussed.

TL;DR: Results provide substantial new evidence that altering the acidic tumor microenvironment is an effective, well tolerated and low cost strategy for the overcoming of anticancer drug resistance.

TL;DR: The growing knowledge of the determinants that confer bortezomib resistance and/or toxicity has provided the basis for the rational development of second generation proteasome inhibitors, some of which were recently approved or that are undergoing clinical evaluation as novel strategies to overcome bortzomib resistant mechanisms and to enhance clinical therapeutic efficacy along with minimal side effects.

TL;DR: This review shows both a medicinal chemists' approach toward the design of third generation EGFR inhibitors as well as a detailed overview of the development of EGFR inhibitor over the last decade.

TL;DR: The key parameters for designing a powerful ADC are reviewed, focusing on how ADCs are addressing the challenge of multiple drug resistance (MDR) and its rational overcoming.

TL;DR: The role of antifungal tolerance in the efficacy of drug treatments is evaluated and the potential mechanisms for this role are evaluated.

TL;DR: A comprehensive update on the most important findings regarding the research of pharmacogenomics markers in the field of CRC treatment that could be integrated in clinical practice in order to accomplish an efficacious personalized treatment is provided.

TL;DR: Recent findings on the dynamic expression of TRAIL death receptors, including the regulatory roles of endocytosis, autophagy, and Ras GTPase-mediated signaling events are highlighted, which could aid in the identification of novel predictive biomarkers of tumor response as well as the development of combinational drugs to overcome or bypass tumor drug resistance to TRAIL receptor-targeted therapies.

TL;DR: The present review describes the main pathways that are modulated by TS-targeting anticancer drugs starting from the description of the normal functioning of the folate metabolic pathway, through the protein modulation occurring upon drug delivery to cultured tumor cells as well as cancer patients, and finally describing how the pathways areModulated by drug resistance development.

TL;DR: The role of Rho subfamily of proteins in cancer is discussed, and their involvement in intrinsic and acquired drug resistance is focused on.

TL;DR: A complete understanding of DNA-unrelated effects of platinum compounds might reveal new aspects of drug resistance allowing the implementation of the antitumor therapeutic efficacy of platinum compound-based regimens and minimization of their toxic side effects.

TL;DR: Overall, the possible approaches to improve the efficacy and safety of ion channel targeting in oncology include the development of specific inhibitors for the channel subtypes expressed in specific tumors; drug delivery into the tumor by using antibodies or nanotechnology-based approaches; and combination regimen therapy and blocking specific conformational states of the ion channel.

TL;DR: This review focuses on host-tumor interactions leading to therapy resistance with special emphasis on different host cells and secreted factors within the tumor microenvironment and the development of novel inhibitors that block the host response to therapy.

TL;DR: Current understanding of UBL deregulation in cancer is summarized and novel opportunities for therapeutic interventions are highlighted, including next generation modulators that can serve as novel therapeutic modalities.

TL;DR: D dormant cancer cells appear to be an important target in the attempt to eradicate residual cancer cells, and eventually cure patients who repeatedly respond to anticancer therapy but lack complete tumor eradication.

TL;DR: The current understanding of the clag multigene family is reviewed, which appears to be central to host-parasite interactions and an important therapeutic target.

TL;DR: The potential of DUB inhibitors to circumvent acquired drug resistance and provide a therapeutic option for the treatment of cancer isdiscussed.

TL;DR: CPE are increasing in Sweden, but are still at a comparably low level, and isolates were categorised as possible XDR (extensively drug-resistant) in 26/94 cases.